Demo Account   Live Account  

Newsroom

  • Share:

Apellis Pharmaceuticals gets FDA approval for eye disease drug

By Liz Moyer

Investing.com -- Shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) rose 6.95% before being halted on Nasdaq on Friday.

The Food and Drug Administration approved the company’s Syfovre drug used to treat geographic atrophy (GA) secondary to age-related macular degeneration, a type of eye disease. The company said in a statement that Syfovre is the first and only FDA-approved treatment for GA, which it called “a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide.”

GA is an advanced form of age-related macular degeneration. Cedric Francois, M.D., Ph.D., co-founder and CEO of Apellis said: “GA is a complex disease that the field has spent decades trying to address, so we are humbled and proud to bring forward the first-ever treatment.”

Shares of other drug makers with treatments for forms of macular degeneration were rising on Friday. Regeneron Pharmaceuticals Inc (NASDAQ:REGN), which makes Eylea, was up 2%, though it was down 0.2% in after-hours trading. Roche Holding AG (OTC:RHHVF) Participation (SIX:ROG) shares rose 1.4% during the session on Friday. Roche's Genentech makes Vabysmo, which the FDA approved a little more than a year ago.

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

English Footer

Office network

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201)

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

www.onefinancialmarkets.com is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015
Saudi Money Expo

Broker of the Year
Online Trading – Middle East
IAIR Awards

Best Forex
Customer Service 2018
JFEX Awards

We accept the following payment methods:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.